Mono Pharmacare Limited IPO – GMP, Review, Share Price, Subscription, and Details

1.Mono Pharmacare Limited IPO Overview

The initial public offering (IPO) of Mono Pharmacare Limited is a public issue under the SME board. The subscription window is scheduled to open on Aug 28, 2023 and close on Aug 30, 2023, with the price band fixed at ₹26–28 per equity share.

2.Issue Details at a Glance

3.Bidding, Allotment & Listing Timeline

• Bidding opens: Aug 28, 2023
• Bidding closes: Aug 30, 2023
• Allotment date: TBA
• Listing date: 2023-09-07
• Minimum investment: ₹1,04,000 for 4000 shares

4.Mono Pharmacare Limited IPO GMP Today

No grey market premium has been recorded for Mono Pharmacare Limited yet. GMP is an informal, unregulated indicator of listing-day sentiment and is not published by any exchange.

5.How to Apply for Mono Pharmacare Limited IPO

1. 1Open IPOGMPTracker or use your broker's app or net banking ASBA facility.
2. 2Search for "Mono Pharmacare Limited IPO" and select it from the list of current issues.
3. 3Choose your demat account and enter your bid quantity in multiples of the 4000-share lot, at a price within the ₹26–28 band (or bid at cut-off, if eligible).
4. 4Submit the application and approve the UPI mandate request when it arrives — funds stay blocked in your account and are debited only on allotment.

Allotment is expected to be finalised around TBA, with listing tentatively scheduled for 2023-09-07 on BSE and NSE. Once finalised, check your status on the Mono Pharmacare Limited IPO allotment status page.

6.How to Track Subscription & Allotment

• Live subscription: Track QIB, NII and retail bidding on the IPO subscription status page
• Allotment status: Check your application on the IPO allotment status page
• Full IPO details: See dates, lot size, reservation and financials on the Mono Pharmacare Limited IPO page
• More issues: Browse current IPOs, upcoming IPOs and the IPO event calendar

7.Conclusion

Mono Pharmacare Limited opens on Aug 28, 2023 and closes on Aug 30, 2023 at ₹26–28 per share. Read the offer documents in full and consult a qualified adviser before applying — nothing on this page is investment advice.